Experience

Aurobac Therapeutics

• France
• Biotechnology
• 1 - 100 Employee

• Chief Executive Officer

  • Sep 2022 - Present

  Lyon, Auvergne-Rhône-Alpes, France Aurobac Therapeutics is a biotech company founded as a joint venture by Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE and bioMérieux, a world leader in in vitro diagnostics, to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR).



BEAM Alliance, Biotechs of Europe innovating in Anti-Microbial Resistance

• Founder and Board Member

  • Feb 2015 - Present

  Founder and President of the BEAM Alliance from 2015 to 2022. Board Member and Treasurer since April 2022. The BEAM Alliance is an association regrouping Biopharmaceutical companies from Europe innovating in Anti-Microbial resistance R&D. The BEAM Alliance works to improve the regulatory, investment, and commercial environments in Europe for research, development, approval and market viability of new products combating antimicrobial resistance.



GENFIT

• France
• Biotechnology
• 100 - 200 Employee

• Board Member

  • May 2008 - Present

  Lille Area, France

• VP, COO, CBO and Co-founder

  • Sep 1999 - May 2008

  Lille Area, France GENFIT (Euronext: GNFT; ISIN: FR0004163111), is a late-stage biopharmaceutical company located in Lille (France) and Boston (USA), dedicated to the discovery and development of innovation therapeutic and diasgnostic solutions in metabolic and liver related diseases where there are considerable unmet medical needs.



DA VOLTERRA

• France
• Biotechnology Research
• 1 - 100 Employee

• CEO

  • May 2008 - Aug 2022

  Paris Area, France Da Volterra is French biotech company that develops innovative products to protect the intestinal microbiota from the consequences of drug-induced dysbiosis, and in particular antibiotics and some chemotherapies, to respond to growing unmet medical needs in the fields of oncology. Da Volterra has been developing a unique first-in-class oral late clinical stage product designed to capture drug residues in the gut and abrogate their harmful impact on the microbiota, targeting cancer patients:… Show more Da Volterra is French biotech company that develops innovative products to protect the intestinal microbiota from the consequences of drug-induced dysbiosis, and in particular antibiotics and some chemotherapies, to respond to growing unmet medical needs in the fields of oncology. Da Volterra has been developing a unique first-in-class oral late clinical stage product designed to capture drug residues in the gut and abrogate their harmful impact on the microbiota, targeting cancer patients: (i) to preserve the efficacy of immune checkpoint inhibitors in solid tumor patients taking antibiotics, (ii) to decrease occurrence of life-threatening inter-current complications leading to non-relapse mortality such as severe infections and GvHD in patients with hematological malignancies, and (iii) to limit the occurrence and severity of chemotherapy-induced gut side effects which otherwise lead to suboptimal dosage or cessation of therapy. Show less



Eurasanté

• France
• Research

• Biotech Project Manager - Business Development, Tech tranfer & Start-up Incubation

  • Mar 1997 - Sep 1999

  Lille Area, France Lille Northern France Health Cluster, economic development agency dedicated to tech transfer and business development in life sciences. Bioincubator and biobusiness Park.